2022 World Conference on Lung Cancer (ePosters)-EP16.03-019. Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma

Pdf Summary

A study evaluated the landscape of EGFR extracellular domain (ECD) mutations in advanced non-small cell lung carcinoma (NSCLC) using plasma cell-free DNA (cfDNA) next-generation sequencing (NGS). The aim was to identify potential targeted therapies for this patient population. The analysis, which included the largest cohort to date, found that EGFR ECD mutations are prevalent in the 5' exons of the ECD protein. These mutations do not appear to be mutually exclusive with other oncogenic driver mutations, with KRAS G12X mutations being the most common co-occurring mutation. Further evaluation is needed to understand the functional impact and therapeutic opportunities for NSCLC patients with EGFR ECD mutations. <br /><br />The study analyzed data from clinical plasma cfDNA NGS assays performed on patients with stage IIIB or IV lung cancer between 2018 and 2021. The prevalence of EGFR ECD alterations was analyzed, and it was found that 2,065 out of 14,837 patients had EGFR ECD mutations. Of these, 1,033 patients had EGFR ECD mutations co-occurring with other driver mutations. The majority of EGFR ECD mutations were detected in the 5' region of the protein. The study also identified the most frequently observed EGFR ECD mutations, including EGFR L62R, EGFR R108K, EGFR E114K, EGFR R229C, EGFR A289T/A289V, and EGFR V592I.<br /><br />This study provides important insights into the landscape of EGFR ECD mutations in NSCLC and highlights the potential for targeted therapies for patients with these mutations. Further research is needed to better understand the functional impact of these mutations and to develop effective treatment strategies for this patient population.

Asset Subtitle

Lesli A Kiedrowski

Meta Tag

Speaker Lesli A Kiedrowski

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

EGFR extracellular domain mutations

non-small cell lung carcinoma

plasma cell-free DNA

next-generation sequencing

targeted therapies

oncogenic driver mutations

KRAS G12X mutations

functional impact

therapeutic opportunities

stage IIIB or IV lung cancer